Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: A prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen

Journal of Clinical Oncology

Volumn 23, Issue 13, 2005, Pages 2980-2987

  Rouanet, Philippe ^a   Linares Cruz, Gustavo ^a   Dravet, François ^a   Poujol, Sylvain ^a   Gourgou, Sophie ^a   Simony Lafontaine, Joelle ^a   Grenier, Jean ^a   Kramar, Andrew ^a   Girault, Jean ^a   Le Nestour, Elisabeth ^a   Maudelonde, Thierry ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; CYCLINE; ESTROGEN RECEPTOR; KI 67 ANTIGEN; 4-HYDROXYTAMOXIFEN; ANTIESTROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; TAMOXIFEN;

ABDOMINAL PAIN; ADULT; AGED; APOPTOSIS; ARTICLE; BIOPSY TECHNIQUE; BREAST CANCER; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; FEMALE; GEL; HEADACHE; HOT FLUSH; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE DRUG DOSE; TREATMENT RESPONSE; ADJUVANT THERAPY; BIOPSY; BREAST TUMOR; DOSE RESPONSE; DRUG POTENTIATION; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOLOGY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BIOPSY; BREAST NEOPLASMS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; POSTMENOPAUSE; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 21144447743     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.06.064     Document Type: Article

References (22)

1. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998
2. Jordan VC, Collins MM, Rowsny L, et al: A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75:305-316, 1977
3. Malet C, Gompel A, Spritzer P, et al: Tamoxifen and hydroxytamoxifen isomers versus estradiol effects on normal human breast cells in culture. Cancer Res 48:7193-7199, 1988
4. Mauvais-Jarvis P, Baudot N, Castaigne D, et al: Trans-4-Hydroxytamoxifen concentration and metabolism after local percutaneous administration to human breast. Cancer Res 46:1521-1525, 1986
5. Pujol H, Girault J, Rouanet P, et al: Phase I study of percutaneous 4-hydroxy-tamoxifen with analyses of 4-hydroxy-tamoxifen concentrations in breast cancer and normal breast tissue. Cancer Chemother Pharmacol 36:493-498, 1995
6. Gerdes J, Lemke H, Baisch, et al: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710-1715, 1984
7. Schluter C, Duchrow M, Wohlensberg C, et al: The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements representing a new kind of cell maintaining proteins. Cell Biol 123:513-522, 1993
8. Waseem NH, Lane DP: Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA): Structural conservation and the detection of the nucleolar form. J Cell Sci 96:121-129, 1990
9. Cattoretti G, Becker MHG, Key G, et al: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168:357-363, 1992
10. Chang K, Lee T, Linares-Cruz G, et al: Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril 63:785-791, 1995
11. Linares-Cruz G, Bruzzoni-Giovanelli H, Alvaro V, et al: p21WAF-1 reorganizes the nucleus in tumor suppression. Proc Natl Acad Sci U S A 95:1131-1135, 1998
12. Nemani M, Linares-Cruz G, Bruzzoni-Giovanelli H, et al: Activation of the human homologue of the Drosophila sina gene in apoptosis and tumor suppression. Proc Natl Acad Sci U S A 93:9039-9042, 1996
13. Korenman SG, Stevens RH, Carpenter LA, et al: Estradiol radioimmunoassay without chromatography: Procedure, validation and normal values. J Clin Endocrinol Metab 38:718-720, 1974
14. Bevitt D, Milton ID, Piggot N, et al: New monoclonal antibodies to estrogen and progesterone receptors effective for paraffine section immunohistochemistry. J Pathol 183:228-232, 1997
15. Girault J, Istin B, Fourtillan JB: Quantitative measurement of 4-hydroxytamoxifen in human plasma and mammary tumours by combined gas chromatography/negative chemical ionization mass spectrometry. Biol Mass Spectrom 22:395-402, 1993
16. Robertson JF, Nicholson RI, Bundred NJ, et al: Comparison of the short-term biological effects of 7α-[9-(4,4,5,5,5- pentafluoropentysulfinyl)-nonyl] estra-1,3,5(10)-triene-3,17β-diol (Faslodex) versus Tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 61:6739-6746, 2001
17. Mandlekar S, Yu R, Tan TH, et al: Activation of caspase-3 and c-jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res 60:5995-6000, 2000
18. Obrero M, Yu DV, Shapiro DJ: Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. J Biol Chem 277:45695-45703, 2002
19. Powles T, Eeles R, Ashley S, et al: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352:98-101, 1998
20. Veronesi U, Maisonneuve P, Sacchini V, et al: Italian Tamoxifen Study Group: Tamoxifen for breast cancer among hysterectomised women. Lancet 359:1122-1124, 2002
21. IBIS investigators. First results from the international breast cancer intervention study (IBIS-1): A randomised prevention trial. Lancet 360:817-824, 2002
22. Fisher B, Dignam J, Wolmark N, et al: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353:1993-2000, 1999